Aarti Pharmalabs Q3 FY26 Earnings Call Transcript Released; Interim Dividend Declared
Aarti Pharmalabs released its Q3 FY26 earnings call transcript. Q3 standalone revenue was ₹425 crore, with profit after tax at ₹44 crore. An interim dividend of ₹1.5 per share was declared. The company expects FY26 EBITDA to be flat to marginally growing due to Atali plant delays and API softness. Xanthine expansion targets mechanical completion by March 2026.
The announcement contains financial results for the quarter, an interim dividend declaration, and updates on expansion projects. The decline in key financial metrics and revised EBITDA guidance for the full year, balanced by progress in expansion and dividend, suggests a medium impact on investor sentiment.
The company reported a year-on-year decline in revenue, EBITDA, and profit after tax for Q3 FY26. While an interim dividend was declared and expansion projects are progressing, the downward revision of EBITDA guidance for FY26 due to operational delays and segment softness warrants a neutral sentiment.
Aarti Pharmalabs Limited has released the transcript of its earnings conference call for the third quarter and nine months ended FY26, which was held on February 10, 2026. The company reported standalone revenues of ₹425 crore for Q3 FY26, a decrease from ₹471 crore in the previous year. EBITDA stood at ₹103 crore, down from ₹115 crore year-on-year, and profit after tax was ₹44 crore, compared to ₹74 crore in the corresponding period last year.
The company operates across three key verticals: Xanthine Derivatives (49% of turnover), API and Intermediates (39% of turnover), and CDMO/CMO services (12% of revenue). The API business is experiencing margin pressure, though early signs of recovery are emerging. The CDMO/CMO segment is working with 21 customers and has 59 active projects, with 40 in the commercial stage. The company is confident of meeting its CDMO revenue guidance for FY26 but anticipates exceeding the target may be difficult due to project delivery delays.
Expansion projects are underway, with the Atali plant starting production of qualifying batches in Q3 FY26, though facing some initial hiccups that are expected to be resolved by the end of the current quarter. The Xanthine expansion is progressing, targeting mechanical completion by the end of March 2026, with incremental capacity becoming available in Q1 FY27.
For the full year FY26, the company expects EBITDA to be largely in line with the previous year, with only marginal growth, primarily due to the delay in Atali plant stabilization and softness in the API and intermediate business. The Board has declared an interim dividend of ₹1.5 per share. The transcript also details discussions on business segments, future outlook, capacity expansions, and financial performance during the Q&A session.
What to do with a filing like this
Aarti Pharmalabs Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarti Pharmalabs Limited. Read the original for the full detail.